IP Verse

Vanda Pharmaceuticals Inc. V. Teva Pharmaceuticals U.S.A., Inc. - 1:23-cv-00152

Explore the details of the Vanda Pharmaceuticals Inc. V. Teva Pharmaceuticals U.S.A., Inc. case under case number 1:23-cv-00152 involving a cause of action for Patent Infringement. Review key information about the parties involved, the patents in question, and the docket entries.

Case Details

Case Number
1:23-cv-00152
Filing Date
Feb 10, 2023
Cause of Action
Patent Infringement
Status
-
Nature of Suit
Patent

Parties Involved in the Case

The following parties are involved in this case, with their respective legal representatives for the case.

NameRepresented By
Vanda Pharmaceuticals Inc. -
Teva Pharmaceuticals U.S.A., Inc. -

Patents Involved in the Case

Patents not found - set an alert to get notified when patents are added.

Docket Entries

The Docket Entries section provides a chronological list of all significant filings and court actions in this case.

DateDocket EntryType

Set alerts for critical docket entry

Jul 1, 2025STIPULATION TO EXTEND TIME for Plaintiff to file its Reply Brief in Support of its Motion to Dismiss inequitable Conduct and Antitrust Counterclaims Under Rule 12(b)(6) to July 9, 2025 - filed by Vanda Pharmaceuticals Inc.. (Silver, Daniel) (Entered: 07/01/2025)PACER Document
Jun 9, 2025Pro Hac Vice Fee - Credit Card Payment received for Brady P. Gleason. ( re 195 MOTION for Pro Hac Vice Appearance of Attorney Brady P. Gleason )( Payment of $ 50, receipt number ADEDC-4706405).(Hoeschen, Nathan) (Entered: 06/09/2025)PACER Document
Jun 9, 2025SO ORDERED, re 195 Motion for Pro Hac Vice Appearance of Attorney Brady P. Gleason filed by Teva Pharmaceuticals U.S.A., Inc. Ordered by Judge Jennifer L. Hall on 6/9/2025. (ceg)PACER Document
Jun 9, 2025Pro Hac Vice Attorney Brady P. Gleason for Teva Pharmaceuticals U.S.A., Inc.,Brady P. Gleason for Teva Pharmaceuticals U.S.A., Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. Associated Cases: 1:23-cv-00152-JLH, 1:24-cv-00018-JLH(scs)PACER Document
Jun 24, 2025SO ORDERED, re (79 in 1:24-cv-00018-JLH, 200 in 1:23-cv-00152-JLH) Stipulation and Order to Extend the Deadline for Plaintiff's Reply Brief In Support of its Motion to Dismiss Inequitable Conduct and Antitrust Counterclaims Under Rule 12(b)(6) to July 2, 2025. (*Reset Briefing Schedule re D.I. 187 in 23-cv-152-JLH and D.I. 67 in 24-cv-18-JLH MOTION to Dismiss Based upon Inequitable Conduct and Antitrust Counterclaims Under Rule 12(b)(6): Reply Brief due 7/2/2025). Ordered by Judge Jennifer L. Hall on 6/24/2025. Associated Cases: 1:23-cv-00152-JLH, 1:24-cv-00018-JLH(ceg)PACER Document
Jul 2, 2025SO ORDERED, re (201 in 1:23-cv-00152-JLH, 80 in 1:24-cv-00018-JLH) Stipulation and Order to Extend the Deadline for Plaintiff's Reply Brief in Support of its Motion to Dismiss Inequitable Conduct and Antitrust Counterclaims Under Rule 12(b)(6) to July 9, 2025. (*Reset Briefing Schedule re D.I. 187 in 23-cv-152-JLH and D.I. 67 in 24-cv-18-JLH MOTION to Dismiss Based upon Inequitable Conduct and Antitrust Counterclaims Under Rule 12(b)(6): Reply Brief due 7/9/2025). Ordered by Judge Jennifer L. Hall on 7/2/2025. Associated Cases: 1:23-cv-00152-JLH, 1:24-cv-00018-JLH(ceg)PACER Document
Jul 7, 2025NOTICE OF SERVICE of Defendants' Supplemental Initial Invalidity Contentions filed by Teva Pharmaceuticals U.S.A., Inc..(Hoeschen, Nathan) (Entered: 07/07/2025)PACER Document
Jul 9, 2025REPLY BRIEF re 187 MOTION to Dismiss Based upon Inequitable Conduct and Antitrust Counterclaims Under Rule 12(b)(6) filed by Vanda Pharmaceuticals Inc.. (Silver, Daniel) (Entered: 07/09/2025)PACER Document
Jul 10, 2025NOTICE requesting Clerk to remove Christopher M. Bruno as co-counsel.. (Silver, Daniel) (Entered: 07/10/2025)PACER Document
Jul 11, 2025REQUEST for Oral Argument by Vanda Pharmaceuticals Inc. re (187 in 1:23-cv-00152-JLH) MOTION to Dismiss Based upon Inequitable Conduct and Antitrust Counterclaims Under Rule 12(b)(6), (67 in 1:24-cv-00018-JLH) MOTION to Dismiss Based upon Inequitable Conduct and Antitrust Counterclaims Under Rule 12(b)(6). (Silver, Daniel) (Entered: 07/11/2025)PACER Document
Jul 22, 2025NOTICE OF SERVICE of Subpoenas on Amneal Pharmaceuticals, Inc. filed by Vanda Pharmaceuticals Inc..(Silver, Daniel) (Entered: 07/22/2025)PACER Document
Jul 22, 2025NOTICE OF SERVICE of Subpoenas on MSN Pharmaceuticals Inc. filed by Vanda Pharmaceuticals Inc..(Silver, Daniel) (Entered: 07/22/2025)PACER Document
Jul 22, 2025Interim STATUS REPORT by Vanda Pharmaceuticals Inc.. (Silver, Daniel) (Entered: 07/22/2025)PACER Document